<DOC>
	<DOCNO>NCT00303134</DOCNO>
	<brief_summary>The purpose study test safety efficacy islet cell transplant treatment type 1 diabetes mellitus . It show normal control blood sugar level prevent progression complication ( kidney disease , nerve damage , vascular disease ) diabetes . This research study design see normal blood sugar control achieve transplant pancreatic islet cell liver , may reduce eliminate need insulin . Patients may qualify participate research study type 1 diabetes mellitus least five year meet least one follow criterion : - Experience hypoglycemic unawareness - Defined inability tell blood glucose low ( example , may feel symptom shake , sweat , rapid heartbeat usually signify glucose low ) - Have hospitalize several time past year low blood sugar and/or high blood sugar - Have complication diabetes retinopathy , kidney problem , neuropathy</brief_summary>
	<brief_title>Islet Cell Transplants Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Enrolling subject must Type 1 diabetes mellitus 5 year , complicate least one follow situation persist despite intensive insulin management effort . ( Intensive management define monitor glucose value home less three time day administration three insulin injection day . Such management must monitor close cooperation endocrinologist primary care physician , define least three contact previous 12 month . If endocrinologist participate ongoing management effort past year , independent endocrinologist must assess adequacy management effort prior enrollment . ) The complicate situation : . Reduced awareness hypoglycemia , define absence adequate autonomic symptom plasma glucose level &lt; 54 mg/dL , b. Metabolic lability/instability , characterize two episode severe hypoglycemia associate blood glucose 54 mg/dl OR two hospital visit diabetic ketoacidosis last year , c. Despite effort optimal glucose control , progressive secondary complication diabetes define : ) Retinopathy—a minimum three step progression use Early Treatment Diabetic Retinopathy Study ( ETDRS ) grade system 44 , equivalent progression certify ophthalmologist familiar diabetic retinopathy , ii ) Nephropathy—a confirm rise 50 µg/min ( 72 mg/24h ) microalbuminuria great least three month ( begin anytime within past two year ) despite use ACE inhibitor , iii ) Neuropathy—persistent progress autonomic neuropathy ( gastroparesis , postural hypotension , neuropathic bowel bladder ) persistent progress severe peripheral painful neuropathy respond usual management ( e.g. , tricyclic , gabapentin , carbamazepine ) . 1 . Severe coexist cardiac disease , characterize one condition : Recent myocardial infarction ( within past six month ) , Angiographic evidence noncorrectable coronary artery disease , Evidence ischemia functional cardiac exam ( functional testing require subject , stress echo test recommend subject history ischemic disease ) . Patients unable perform exercise stress echocardiogram test undergo adenosine vasodilator stress test , history bronchospasm , undergo dobutamine stress test . 2 . Active alcohol substance abuseincludes cigarette smoking ( must abstinent six month ) . Active alcohol abuse consider use current NIAAA definition , whereby alcohol abuse define pattern drinking accompany one follow situation within 12month period : Failure fulfill major work , school , home responsibility ; Drinking situation physically dangerous , drive car operate machinery ; Recurring alcoholrelated legal problem , arrest drive influence alcohol physically hurt someone drunk ; Continued drink despite ongoing relationship problem cause worsened effect alcohol . 3 . Psychiatric disorder make subject suitable candidate transplantation , e.g. , schizophrenia , bipolar disorder , major depression unstable uncontrolled current medication . ( A psychological psychiatric consultation require consider necessary current indication history . ) 4 . History nonadherence prescribe regimens 5 . Active infection include hepatitis C , hepatitis B , HIV , TB ( treatment suspect TB ) 6 . Any history current malignancy except squamous basal skin cancer 7 . BMI &gt; 26 kg/m2 8 . Cpeptide response arginine stimulation ( 5 gm I.V . ) ( Cpeptide ≥ 0.3 ng/mL 2 , 3 , 4 , 5 , 7 10 min postinfusion ) 9 . Inability provide inform consent 10 . Age le 18 great 65 year 11 . Creatinine clearance &lt; 80 mL/min/1.73 m2 12 . Serum creatinine &gt; 1.6 mg/dL 13 . Macroalbuminuria ( urinary albumin excretion rate &gt; 300 mg/24h ) 14 . Baseline Hb &lt; 10.5 gm/dL woman , &lt; 13 gm/dL men 15 . Baseline LFT 's outside normal range exception Gilberts Syndrome . ( An initial LFT test panel value &gt; 1.5 time upper limit normal exclude patient ; retest value normal 1.5 time normal make , value remain elevated normal limit , patient exclude . ) 16 . Presence gallstone ( subject may eligible two week laparoscopic cholecystectomy ) 17 . Portal hypertension , detect baseline duplex ultrasonography ( assessment direction flow right , leave main portal vein [ antegrade ( normal ) retrograde ( abnormal indicative portal hypertension ) ] ; hemangioma liver baseline ultrasonography 18 . Untreated proliferative retinopathy 19 . Positive pregnancy test , intent future pregnancy male subject ' intent procreate , failure follow effective contraceptive measure , presently breastfeed 20 . Evidence sensitization PRA ( determine demonstration positive result antiHLA antibody use solid phase immunoassay soluble HLA Class I molecules target , general PRA panel reactivity &gt; 20 % ) 21 . Insulin requirement &gt; 0.7 IU/kg/day 22 . HbA1C &gt; 12 % 23 . Inability reach study hospital transplantation within 24 hrs notification 24 . Untreated hyperlipidemia ( fast LDL cholesterol &gt; 130 mg/dL and/or fast triglyceride &gt; 200 mg/dL ) 25 . Treated hyperlipidemia uncontrolled ( fast LDL cholesterol &gt; 130 mg/dL ; and/or fast triglyceride &gt; 200 mg/dL ) 26 . Under treatment medical condition require chronic use steroid aa . Use coumadin anticoagulant therapy ( except aspirin ) subject PT/INR &gt; 1.5 27 . Addison 's disease . All subject screen basal 8:00 a.m. cortisol test . Results less low limit normal indicate testing ( e.g. , Cortrosyn stimulation test ) rule adrenal insufficiency . Abnormal ACTH stimulation test exclusion criterion .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2007</verification_date>
	<keyword>islet cell</keyword>
	<keyword>diabetes</keyword>
	<keyword>transplant</keyword>
	<keyword>immunosuppression</keyword>
	<keyword>autoimmunity</keyword>
	<keyword>alloimmunity</keyword>
</DOC>